Research Frontiers Inc. (Nasdaq: REFR) announced its financial results for its fourth quarter and full year 2025. Management will host a conference call today at 4:30 p.m. Eastern Time to discuss its ...
Data readout for SIM0505/CDH6 ADC Phase 1 dose escalation study and initiation of dose optimization in ovarian cancer are both anticipated in Q2 2026LNCB74 Phase 1 dose escalation trial update planned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results